Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing products that address unmet patient needs, particularly in the treatment of pulmonary arterial hypertension (PAH). The company leverages its proprietary PRINT® technology, a particle engineering platform, to create highly uniform drug particles with precise control over size, shape, and chemical composition. This technology enables Liquidia to engineer desirable pharmacological benefits into its products, such as prolonged drug release, increased drug loading, and enhanced stability.

Liquidia operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of PAH and pulmonary arterial hypertension associated with interstitial lung disease (PH-ILD). Meanwhile, Liquidia PAH commercializes rare disease pharmaceutical products, including generic Treprostinil Injection.

Liquidia Corporation is a biopharmaceutical company committed to developing and commercializing innovative therapies for patients with rare cardiopulmonary diseases. They focus on improving the treatment of pulmonary arterial hypertension (PAH) and pulmonary arterial hypertension associated with interstitial lung disease (PH-ILD) by utilizing their proprietary PRINT® Technology to engineer precise and uniform drug particles. This allows for the creation of products with enhanced efficacy, safety, and delivery, ultimately improving the lives of patients and healthcare providers.

Liquidia Corporation promotes a culture focused on innovation and collaboration, emphasizing the development and commercialization of novel therapies for patients with rare cardiopulmonary diseases. The company is committed to bringing its PRINT® Technology to address unmet patient needs, fostering an environment where employees are encouraged to contribute their expertise and work together towards common goals.